Targeting Inflammation in Atherosclerotic Disease - The New Frontier-Residual Inflammatory Risk in the PostPCI/AMI Patient: How Do We Define and Reduce These Risks? Dr. Wayne B. Batchelor

Residual Inflammatory Risk in the PostPCI/AMI Patient: How Do We Define and Reduce These Risks? Dr. Wayne B. Batchelor

Video Transcription

Video Summary

The speaker emphasizes the importance of focusing on inflammation in interventional cardiology, acknowledging advancements in reducing ischemic events post-PCI. While current treatments have significantly improved patient outcomes, a residual risk remains due to inflammation, which persists after myocardial infarctions and PCI procedures. High-sensitivity CRP is highlighted as a significant marker for inflammation prediction. The speaker discusses the CANTOS trial and supersaturated oxygen treatment, noting challenges with broader adoption due to feasibility. The pending Artemis trial is highlighted as crucial for understanding inflammation-targeting therapies to further reduce cardiovascular risk without compromising patient safety.

Keywords

inflammation

interventional cardiology

CANTOS trial

high-sensitivity CRP

Artemis trial